Supplemental Materials: The Two-dose MVA-BN Mpox Vaccine Induces a Nondurable and Low Avidity MPXV-specific Antibody Response

Aaron L. Oom, Kesi K. Wilson, Miilani Yonatan, Stephanie Rettig, Heekoung Allison Youn, Michael Tuen, Yusra Shah, Ashley L. DuMont, Hayley M. Belli, Jane R. Zucker, Jennifer B. Rosen, Ramin Sedaghat Herati, Marie I. Samanovic, Ralf Duerr, Angelica C. Kottkamp, and Mark J. Mulligan on behalf of the NYC OSMI Study Group

		Prior			Dose	Dose	Dose	Dose	
	Age	Smallpox	HIV	Received	1	1	2	2	Sample
Participant	Range	Vaccination	Status	Tecovirimat?	DPO	Route	DPO	Route	DPO
Conv 1	40-50	No	PWH	Yes	-25	SC	46	ID	340
Conv 2	30-40	No	HIV	No	9	SC	87	П	336
001172	00 40	NO	uninfected	110	0	00	01		000
Conv 3	20-30	No	HIV	Yes	-1	SC			386
00111 0	20 00		uninfected	100	•	00			000
Conv 4	40-50	No	PWH	Yes	78	ID			388
Conv 5	30-40	No	PWH	Yes					335
Conv 6	50-60	Yes	PWH	Yes					338
Conv 7	60-70	Yes	PWH	No					391
Conv 8	60-70	Yes	PWH	No					433
Conv 9	30-40	No	PWH	No					386

Table S1: Sample information for convalescent participants.

Participants above the horizontal line received one or two doses of MVA-BN. Conv, convalescent; PWH, person with HIV; SC, subcutaneous; ID, intradermal; DPO, days post-symptom onset.

Naïve CD4 Counts	Exp CD4 Counts
267	284
321	350
347	351
491	438
500.5	450
574.5	482.5
576	538.5
648	552
744	600.5
750	675
797	680
842	680
907	685
1387	703
1500	751.5
	755
	760
	859
	876
	890
	902
	948
	996
	1069
	1124

Table S2: CD4 counts at time of enrollment for OSMI participants with HIV.

Exp, prior smallpox vaccination.

Table S3: Linear mixed-effects model parameters for naïve participants using days post dose 2 (DPV2), age, HIV status, route of administration, and dosing interval as fixed effects and subject (OSMI) as a random effect; age is no longer significant following the removal of HIV status and route of administration.

log(Neut)				
Predictors	Estimates	CI	р	
(Intercept)	4.4587	3.9333 – 4.9842	<0.0001	
DPV2	-0.0041	-0.0047 – -0.0035	<0.0001	
Age	-0.0146	-0.0281 – -0.0011	0.0347	
HIV [Pos]	0.0068	-0.2609 - 0.2745	0.9599	
Route [ID-SC]	0.3527	-0.0468 - 0.7522	0.0833	
Route [SC-ID]	0.1622	-0.0967 – 0.4211	0.2181	
Route [SC-SC]	0.1504	-0.1429 - 0.4438	0.3131	
Interval	0.0030	0.0008 – 0.0052	0.0084	
Random Effects				
σ^2		0.17		
T ₀₀ OSMI	0.13			
ICC	0.43			
N _{OSMI}	100			
Observations	207			
Marginal R ² / Conditional R ²	0.467 / 0.694			
REML Criterion at Convergence		354.5		

 Table S4: Linear mixed-effects model parameters for experienced participants using days post dose 2 (DPV2), dosing interval, route of administration, age, and HIV status as fixed effects and subject (OSMI) as a random effect.

In(Neut)				
Predictors	Estimates	CI	р	
(Intercept)	4.1590	2.3366 – 5.9814	<0.0001	
DPV2	-0.0018	-0.0024 – -0.0011	<0.0001	
Age	0.0142	-0.0081 - 0.0366	0.2091	
HIV [Pos]	0.1068	-0.2439 – 0.4575	0.5469	
Route [ID-ID]	-0.0481	-1.3567 – 1.2605	0.9420	
Route [ID-SC]	-0.4648	-1.8034 – 0.8739	0.4923	
Route [SC-ID]	-0.1868	-1.4623 – 1.0886	0.7718	
Route [SC-SC]	-0.2444	-1.5097 – 1.0209	0.7023	
Interval	0.0011	-0.0032 - 0.0054	0.6144	
F				
σ^2		0.11		
Too osmi	0.30			
ICC	0.74			
N _{OSMI}	48			
Observations	106			
Marginal R ² / Conditional R ²	0.153 / 0.779			
REML Criterion at Convergence	187.6			

Table S5: Linear mixed-effects model parameters for naïve PWH using days post dose 2 (DPV2) and CD4 counts as fixed effects and subject (OSMI) as a random effect.

In(Neut)				
Predictors	Estimates	CI	p	
(Intercept)	4.4747	4.0205 - 4.9288	<0.0001	
DPV2	-0.0036	-0.00490.0023	<0.0001	
CD4	-0.0003	-0.0008 - 0.0002	0.2310	
R				
σ^2	0.10			
T ₀₀ OSMI	0.05			
ICC	0.36			
N _{OSMI}	14			
Observations	29			
Marginal R ² / Conditional R ²	0.532 / 0.700			
REML Criterion at Convergence	53.3			

Table S6: Linear mixed-effects model parameters for experienced PWH using days post dose 2 (DPV2) and CD4 counts as fixed effects and subject (OSMI) as a random effect.

In(Neut)				
Predictors	Estimates	CI	р	
(Intercept)	4.5443	3.6179 – 5.4707	<0.0001	
DPV2	-0.0016	-0.00250.0008	0.0004	
CD4	0.0006	-0.0006 - 0.0019	0.3100	
R				
σ^2	0.08			
T ₀₀ OSMI	0.44			
ICC		0.84		
N _{OSMI}	25			
Observations	52			
Marginal R ² / Conditional R ²	0.095 / 0.856			
REML Criterion at Convergence		105.1		

In(Neut)				
Predictors	Estimates	CI	р	
(Intercept)	4.0699	3.8736 – 4.2662	<0.0001	
DPV2	-0.0041	-0.0047 – -0.0035	<0.0001	
Interval	0.0036	0.0014 – 0.0057	0.0011	
Random Effects				
σ^2		0.17		
Тоо озмі	0.13			
ICC		0.44		
N _{OSMI}	100			
Observations	207			
Marginal R ² / Conditional R ²	0.449 / 0.692			
REML Criterion at Convergence		344.6		

 Table S7: Linear mixed-effects model parameters for naïve participants using days post

 dose 2 (DPV2) and dosing interval as fixed effects and subject (OSMI) as a random effect.

Table S8: Linear mix	xed-effects model	parameters for ex	xperienced partic	ipants using days
post dose 2 ((DPV2) as a fixed	effect and subject	t (OSMI) as a ran	dom effect.

In(Neut)					
Predictors	Estimates	CI	р		
(Intercept)	4.9694	4.7733 – 5.1656	<0.0001		
DPV2	-0.0018	-0.00240.0012	<0.0001		
Random Effects					
σ^2	0.11				
T ₀₀ OSMI		0.29			
ICC	0.73				
N _{OSMI}	48				
Observations	106				
Marginal R ² / Conditional R ²	0.091 / 0.754				
REML Criterion at Convergence		170.2			





10

1

V1

V2

V3

V4

V5



10

10

T

Figure S1: Anti-MPXV H3 binding titers follow the general trends of MPXV neutralizing titers. A) Serum anti-MPXV H3 IgG titers were measured by ELISA across all participants and study visits. Colored/black bars on each group indicate the geometric mean titer. Horizontal, dashed black line indicates the limit of detection (endpoint titer of 50) for the assay. Any values below the LoD are denoted as an endpoint titer of 25. B and C) Paired anti-MPXV H3 IgG endpoint titers by visit for naïve (B) or experienced (C) participants. Bolded line in panels B and C indicates the mean titer at each time point. Statistical testing conducted by Kruskal-Wallis test with Dunn's method for multiple comparisons for panel A, and by Wilcoxon matched-pairs signed rank test for panels B and C.

Figure S2



B)

Figure S2: Neutralizing titers elicited by MVA-BN are statistically similar between PWH and HIV-uninfected individuals. A) Aggregate MPXV neutralizing titer data for V4 stratified first by prior smallpox vaccination then by HIV status. Colored/black bars on each group indicate the geometric mean titer. Serum neutralizing titers were measured by a fluorescence-based microneutralization assay using authentic clade IIb MPXV. Horizontal, black dashed line in each panel indicates the positivity threshold for neutralization (Fig. 2). B) Same as A, but for V5. Statistical testing conducted by Kruskal-Wallis test with Dunn's method for multiple comparisons.





Figure S3: Neutralizing titers elicited by intradermal MVA-BN are statistically similar between PWH and HIV-uninfected individuals. A) Aggregate MPXV neutralizing titer data of participants that received at least one dose of MVA-BN intradermally. Titers for V4 are stratified first by prior smallpox vaccination then by HIV status. Colored/black bars on each group indicate the geometric mean titer. Serum neutralizing titers were measured by a fluorescence-based microneutralization assay using authentic clade IIb MPXV. Horizontal, black dashed line in each panel indicates the positivity threshold for neutralization (Fig. 2). B) Same as A, but for V5. Statistical testing conducted by Kruskal-Wallis test with Dunn's method for multiple comparisons.

Figure S4



Figure S4: MPXV neutralizing titers wane significantly faster in naïve MVA-BN vaccinees. Comparison of the paired fold changes in neutralizing titers from Fig. 2B and C. Colored/black bar for each group indicates the geometric mean fold change. Statistical testing conducted by Kruskal-Wallis test with Dunn's method for multiple comparisons.



Naïve

Figure S5: Longer dosing intervals significantly correlate with peak MPXV neutralizing titers in naïve MVA-BN vaccinees. Linear regression of V3 MPXV neutralizing titers versus dosing interval in VACV-naïve participants.



	Naïve V3	Naïve V4	Naïve V5
N	37	54	44
GMT	91.1	46.4	24.0
(95% CI)	(73.9-112.3)	(39.2-54.9)	(20.4-28.3)
Median DPV2	19	82	294
(IQR)	(15-25)	(72-97)	(275-304)
% Neg	0	29.6	81.8

No Prior Smallpox

Vaccination



	Exp V3	Exp V4	Exp V5
Ν	16	35	32
GMT	122.4	116.7	84.8
(95% CI)	(86.5-173.3)	(96.7-140.8)	(65.0-110.7)
Median DPV2	21	81	286
(IQR)	(18-29)	(74-92)	(267-313)
% Neg	0	5.7	15.6

Prior Smallpox

Vaccination

Figure S6: Subsets for multiplexed immunoassay analysis have similar neutralization to overall study groups. A) Aggregate MPXV neutralizing titer data for naïve group subset used in Figures 4 and 5. Serum neutralizing titers were measured by a fluorescence-based microneutralization assay using authentic clade IIb MPXV. Colored/black bars on each group indicate the geometric mean titer. Horizontal, black dashed line indicates the positivity threshold for neutralization (Fig. 2). B) Same as A, but for experienced participants. Exp, experienced vaccinees (prior history of smallpox vaccination).



Proportion Positive by Antigen

A)

B)



Figure S7: MPXV H3 and A35 are immunodominant in all participants and significantly correlate with MPXV neutralization. A) Proportion of participants that are IgG-positive for the indicated MPXV protein at a given time point and prior smallpox vaccination status. B) Spearman correlation for each MPXV protein against neutralizing titers by time point and prior smallpox vaccination status. Significant correlations, i.e., p < 0.05, are denoted with an asterisk. Exp, experienced vaccinees (prior history of smallpox vaccination).